At the time of writing, Immunome Inc [IMNM] stock is trading at $23.48, up 3.71%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMNM shares have gain 23.19% over the last week, with a monthly amount glided 36.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on December 01, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $36. Previously, Goldman started tracking the stock with Buy rating on September 22, 2025, and set its price target to $26. On September 05, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $26 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $23 on April 02, 2025. Stephens initiated its recommendation with an Overweight and recommended $30 as its price target on November 08, 2024. Piper Sandler started tracking with an Overweight rating for this stock on May 31, 2024, and assigned it a price target of $27. In a note dated April 30, 2024, JP Morgan initiated an Overweight rating and provided a target price of $24 on this stock.
For the past year, the stock price of Immunome Inc fluctuated between $5.15 and $25.30. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $23.48 at the most recent close of the market. An investor can expect a potential return of 46.93% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
According to Immunome Inc [NASDAQ:IMNM], the company’s sales were 9.68M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.84%, Pretax Profit Margin comes in at -16.87%, and Net Profit Margin reading is -16.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.87 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.70 points at the first support level, and at 21.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.17, and for the 2nd resistance point, it is at 24.85.
Ratios To Look Out For
It is important to note that Immunome Inc [NASDAQ:IMNM] has a current ratio of 8.90. Also, the Quick Ratio is 8.90, while the Cash Ratio stands at 6.29. Considering the valuation of this stock, the price to sales ratio is 222.45, the price to book ratio is 8.16.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Jun 03 ’25 when 5000.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on Mar 25 ’25 to buy 7800.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 0.14 million shares on Mar 26 ’25.
